Skip to Content

Xhance Approval History

FDA Approved: Yes (First approved September 18, 2017)
Brand name: Xhance
Generic name: fluticasone propionate
Dosage form: Nasal Spray
Previous Name: OPN-375
Company: Optinose US, Inc.
Treatment for: Nasal Polyps

Xhance (fluticasone propionate) is a topical nasal corticosteroid indicated for the treatment of nasal polyps.

Development History and FDA Approval Process for Xhance

DateArticle
Sep 19, 2017Approval Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
Jan 31, 2017OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375
Oct 20, 2010New Data Show Therapeutic Benefits in Chronic Rhinosinusitis Patients Using Fluticasone Delivered by OptiNose's Novel Delivery Technology
Aug 10, 2010OptiNose Announces Publication of Positive Subgroup Analysis Evaluating Efficacy of Fluticasone Delivered with Novel Drug Delivery Technology

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide